<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04627688</url>
  </required_header>
  <id_info>
    <org_study_id>2019-02483</org_study_id>
    <nct_id>NCT04627688</nct_id>
  </id_info>
  <brief_title>Optimization of Diet Before Surgery (OptiSurg)</brief_title>
  <acronym>OptiSurg</acronym>
  <official_title>Optimization of Diet Before Surgery (OptiSurg): Effects of Time Restricted Feeding (TRF) Before Vascular Surgery - An Open-label Randomized Controlled Trial of TRF vs Regular Dietary Advices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching goal of this project is to assess whether a controlled short-term Time&#xD;
      restricted feeding (TRF) intervention leads to metabolic benefits, improves recovery after&#xD;
      vascular surgery and that TRF is safe. Participants suffering from intermittent claudication&#xD;
      (Fontaine stage II peripheral artery disease, PAD) will be randomly assigned to a 2-week TRF&#xD;
      or active control dietary advices before open surgical revascularization. Prior to the&#xD;
      surgery, the investigators will assess the eating patterns of participants with an innovative&#xD;
      smartphone application ('app') which is less intrusive and more reliable than food&#xD;
      diaries/questionnaires to assess eating behavior and patterns. In the second part of the&#xD;
      study, the investigators will investigate whether a short term TRF intervention improves&#xD;
      surgical recovery, in the short-term (1 month, primary endpoint) and long-term (optional, up&#xD;
      to 1 year), as part of the routine clinical follow-up. This proposal builds on established&#xD;
      expertise in the biology of dietary intervention, surgery, and study of eating patterns in&#xD;
      human.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with: Death, Myocardial infarction, Stroke, Surgical re-intervention.</measure>
    <time_frame>1 month</time_frame>
    <description>Safety of TRF before vascular surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of Stay [days]</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic and diastolic blood pressure [mmHg]</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ankle and toe brachial index [0.2-1.4]</measure>
    <time_frame>1 month</time_frame>
    <description>Improvement in limb perfusion measured as an increase in the reported index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight [gram]</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BMI [kg/m^2]</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total cholesterol levels [mg/dl]</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LDL cholesterol levels [mg/dl]</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HDL cholesterol levels [mg/dl]</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in triglyceride levels [mg/dl]</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glycemia [mmol/L]</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin levels [pmol/L]</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c levels [%]</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to TRF intervention</measure>
    <time_frame>1 month</time_frame>
    <description>Adherence will be determined using the smartphone app, by the number of days in which a participant will be adherent to logging and all caloric food items were contained within a 15-min buffer on each side of the selected eating window.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from randomization to the first occurrence of any of the following major thrombotic vascular events: MI (Myocardial infarction), ischemic stroke, CV (Cardiovascular) death, ALI (Acute limb ischemia), and major amputation or death (any cause).</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in interleukin-6,-1, -10 levels [pg/ml]</measure>
    <time_frame>1, 2 days ans 1 month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in tumor necrosis factor alpha levels [pg/mL]</measure>
    <time_frame>1, 2 days ans 1 month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in transforming growth factor beta levels [ng/mL]</measure>
    <time_frame>1, 2 days ans 1 month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in interferon gamma levels [pg/mL]</measure>
    <time_frame>1, 2 days ans 1 month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in cortisol levels [nmol/L]</measure>
    <time_frame>1, 2 days ans 1 month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in thyroid stimulating hormone levels [mIU/L]</measure>
    <time_frame>1, 2 days ans 1 month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in triiodothyronine levels [nmol/L]</measure>
    <time_frame>1, 2 days ans 1 month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in thyroxine levels [μg/d]</measure>
    <time_frame>1, 2 days ans 1 month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in circulating hydrogen sulphide levels</measure>
    <time_frame>1, 2 days ans 1 month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in circadian hormone secretion</measure>
    <time_frame>1, 2 days ans 1 month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in gut microbiome</measure>
    <time_frame>1, 2 days ans 1 month</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Surgery</condition>
  <condition>Time Restricted Feeding</condition>
  <arm_group>
    <arm_group_label>Standard dietary advices</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Time restricted feeding</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Time restricted feeding</intervention_name>
    <description>Participants will be advised to eat only during a selected window of 8 hours, and no later than 4pm, with no advice on nutrition quality, quantity or caloric intake. The intervention will include no medication, no medical device, and will last for 2 weeks prior to surgery.</description>
    <arm_group_label>Time restricted feeding</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard dietary advices</intervention_name>
    <description>Participants will be given standard dietary advices, as recommended by the international nutrition guidelines, and thus are not different from common clinical practice.</description>
    <arm_group_label>Standard dietary advices</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Fontaine stage II peripheral artery disease planned for open femoral endarterectomy&#xD;
&#xD;
          -  Body mass index ≥ 20 kg/m2&#xD;
&#xD;
          -  Smartphone compatible with the app (iOS or Android systems)&#xD;
&#xD;
          -  Hypertensive (or on 1 or more blood pressure lowering medication)&#xD;
&#xD;
          -  Hypercholesterolemia (or on 1 or more lipid lowering medication)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes on insulin therapy or sulfonylureas&#xD;
&#xD;
          -  Fontaine stage III and IV peripheral artery disease&#xD;
&#xD;
          -  Prior revascularization on the index leg within 14 days of the qualifying&#xD;
             revascularization.&#xD;
&#xD;
          -  Major surgery in the past 3 months&#xD;
&#xD;
          -  Myocardial infarction or revascularization (PTA, stent, CABG) in the past 3 months&#xD;
&#xD;
          -  Major illness / fever over the previous month, active cancer&#xD;
&#xD;
          -  On a diet / weight management or prior bariatric surgery&#xD;
&#xD;
          -  Major mental illness, unable to give consent, inability to follow study procedures&#xD;
             (language barrier, dementia)&#xD;
&#xD;
          -  Current shift work or travel abroad planned in the next month&#xD;
&#xD;
          -  Major sleep disorder&#xD;
&#xD;
          -  Enrolled in another interventional clinical trial&#xD;
&#xD;
          -  Ongoing pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alban Longchamp, MD, PhD</last_name>
    <phone>+41 79 556 55 10</phone>
    <email>alban.longchamp@chuv.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>C. Keith Ozaki, M.D.</last_name>
      <phone>857-307-1920</phone>
      <email>ckozaki1@bwh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois (CHUV)</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alban Longchamp, M.D., Ph.D.</last_name>
      <phone>+41 79 556 55 10</phone>
      <email>alban.longchamp@chuv.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Alban Longchamp</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

